Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: A Retrospective Analysis of Twenty-six Patients Treated in One Institution

Abstract

We retrospectively attempted to analyse prognostic factors in a group of 26 patients with centrocytic lymphomas (CCL) treated from 1979 to 1991 (representing 7% of all cases of NHL diagnosed in our institution during that period). Ten of the patients were females and 16 males, and their median age at diagnosis was 69 years (range 38-85). The majority of patients (77%) had advanced disease (Ann Arbor stage III-IV) at presentation. Twenty-two patients (85%) had good performance status (0-1 ECOG). B-symptoms were present in 10 cases. Most patients (87%) presented with generalized adenopathies. Bone marrow involvement was observed in 12 patients (46%) and Waldeyer's ring involvement in 5 (4 of them with stage I-II). In 5 cases the liver was involved and 3 pts had gastrointestinal localizations; 15 patients had more than 2 sites of disease: LDH elevation was observed in 8/24 pts. Fourteen patients (54%) received single-agent chlorambucil (3 pts) or CVP (11 pts). Eleven patients were treated with ADM-containing regimens (7 with CHOP or M-ACOD and 4 with 3rd generation regimens). One patient had radiotherapy alone. The complete response (CR) rate was 50% (13/26); 8 patients relapsed with a median time to progression of 19 months, and only 3 responded to salvage treatment. The median overall survival was 33 months, with fewer than 40% of patients surviving longer than 3 years. At univariate analysis the use of ADM-containing regimens seems significantly correlated with the CR rate (p = 0.047), the failure-free survival (p = 0.023), and the overall survival (p = 0.004).(ABSTRACT TRUNCATED AT 250 WORDS)

Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions

“…4,5 The median survival time is 3 to 5 years and cure is not achieved with current treatment options. 2,[6][7][8][9][10][11] The chromosomal translocation t(11;14)(q13;q32) is characteristic of MCL. This aberration leads to the juxtaposition of the cyclin D1 (CCND1) gene and the immunoglobulin heavy-chain promoter resulting in an overexpression of CCND1.…”

Blastic mantle cell leukemia: A previously undescribed form

“…At the time of diagnosis of mantle cell lymphoma, peripheral blood involvement may be present-13-21% of cases in most studies (9)(10)(11)(12). The leukemic phase of MCL is defined as an absolute lymphocytic count of greater than 4,000/ microliter; Shivdasani et al reported the leukemic phase to be present in 10-20% of patients with MCL (13).…”

Lymphoid Lesions of the Head and Neck: A Model of Lymphocyte Homing and Lymphomagenesis

“…As the nasopharynx is functionally and developmentally linked to the gastrointestinal tract, it is not surprising that this site is commonly involved as well. Waldeyer's ring is involved at presentation in 20% of patients, but the incidence may be greater with a thorough ear, nose, and throat exam and blind biopsies of nasopharyngeal lymphoid tissue (3). The overlying mucosal epithelium is commonly undisturbed.…”

“…This pattern of gastrointestinal tract involvement has been referred to as lymphomatous polyposis (2). Twenty percent of patients with MCL present with overt gastrointestinal tract involvement, but with endoscopic evaluation, the incidence increases to 88% (3,4). As the nasopharynx is functionally and developmentally linked to the gastrointestinal tract, it is not surprising that this site is commonly involved as well.…”